Top Cannabis Investment News, Member Posts, Cannabis Investment Daily Indices and more!

1yr ago Cannabis harrisbricken Views: 365

On June 14, the Sixth Panel (Sexta Turma) of Brazil’s Superior Court of Justice (Superior Tribunal de Justiça, or STJ) issued a decision allowing cultivation of cannabis for medical purposes. The STJ is responsible for uniformizing the interpretation of Brazilian federal law across the country, and serves as the court of final appeal for cases that do not involve constitutional matters. While the STJ decision applies only to the three plaintiffs in the case at hand, it establishes a precedent that lower courts can follow.

Back in March 2021, in Cannabis for Brazilian Pets and Their Humans, we noted that Brazilian courts were granting habeas corpus petitions made by citizens seeking to grow their own cannabis for medical purposes, adding that it would be interesting to see if the trend resulted in judicial decisions of broader application. The STJ has now provided an answer, and one that represents good news for medical cannabis users.

Brazil legalized the prescription of cannabis products for medical use in 2014, but an ongoing prohibition on cultivation under Brazil’s Drugs Law (Law 11.343/06) forced consumers to rely on expensive imports. The three plaintiffs in the STJ decision had authorization from the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária, or Anvisa) to import cannabidiol (CBD), but high import costs compromised their access to their medication.

Explaining the STJ’s reasoning for protecting the plaintiffs against application of the Drugs Law, Minister Sebastião Reis Júnior argued that the legal treatment of cannabis cultivation activities cannot be divorced from their purpose. Where cultivation is part of the pursuit of the right to health, criminalization is unjustified. On this note, the Sixth Panel’s justices criticized the regulators’ failure to provide for legal cultivation for medical and scientific purposes. For Minister Rogerio Schietti Cruz, “this regulatory omission creates a segregation between patients who can afford treatment, importing cannabidiol-based drugs, and those who cannot.”

As noted earlier, the STJ decision applies only to the three plaintiffs in the case. And while the decision could pave the way for similar decisions by lower courts, this would require medical cannabis users to file for relief in the first place. It is possible that the STJ decision, perhaps coupled with a growing number of granted habeas petitions by courts across Brazil, could lead to de facto decriminalization of home cultivation for medical purposes. Ideally, however, regulators will take notice of this call by a top court, and put into place rules that facilitate access to medical cannabis for Brazilians.

Medical Cultivation OK’d in Brazil on Harris Bricken Sliwoski LLP.


Today's Cannabis Investment Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.